Quick Answer
Inmune Bio, Inc. reported Total Assets of $32.35 million for fiscal year 2025.
Inmune Bio, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $32.35M | -18.2% |
| 2024 | $39.56M | -30.6% |
| 2023 | $57.00M | -30.3% |
| 2022 | $81.80M | -18.2% |
| 2021 | $99.94M | +145.8% |
| 2020 | $40.66M | +66.1% |
| 2019 | $24.47M | +40.9% |
| 2018 | $17.36M | -5.7% |
| 2017 | $18.41M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $33.36M | -36.8% | -11.5% |
| June 30, 2025 | $37.68M | -28.2% | -0.3% |
| March 31, 2025 | $37.80M | -19.3% | -4.5% |
| December 31, 2024 | $39.56M | -30.6% | -25.0% |
| September 30, 2024 | $52.78M | -15.8% | +0.6% |
| June 30, 2024 | $52.45M | -24.8% | +12.0% |
| March 31, 2024 | $46.83M | -36.7% | -17.8% |
| December 31, 2023 | $57.00M | -30.3% | -9.1% |
- Inmune Bio, Inc. showed a decrease of -18.2% in Total Assets compared to the prior fiscal year.
- Over the 2017–2025 period, Inmune Bio, Inc.’s total assets has grown by 75.7% (from $18.41 million to $32.35 million).
- The most recent figure is from Inmune Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: